$3.180
+0.061 (+1.92%)At close
SABS News
SABS Events
SAB Biotherapeutics Receives FDA Fast Track Designation
SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a potentially disease-modifying immunotherapy being developed for the treatment of individuals with new-onset Stage 3 type 1 diabetes.
Emergent BioSolutions Signs $50M Agreement with SAB Biotherapeutics
Emergent BioSolutions (EBS) announced a multi-year agreement with SAB Biotherapeutics (SABS) to support the process development and manufacturing of SAB-142, SAB BIO's lead program in clinical development for autoimmune type 1 diabetes. The executed agreement is valued at approximately $50M, of which $36M is contingent on future regulatory approval and downstream milestones. Under the terms of the agreement, Emergent will provide end-to-end development and manufacturing services to SAB BIO that are compliant with current good manufacturing practices. These services will include process development and scale-up, technology and analytical method transfer, manufacturing for SAB-142's ongoing clinical program and commercial manufacturing services upon regulatory approval.
Deal Size Increased to $85M in Common Stock
The deal size was increased to $85M in common stock from $75M in common stock and the range was $3.75-$4.07. Jefferies, UBS, Citi and Barclays acted as joint book running managers for the offering.
Jefferies, UBS, Citi, and Barclays Jointly Manage Offering
Jefferies, UBS, Citi and Barclays are acting as joint book running managers for the offering.
SAB Biotherapeutics Commences Underwritten Public Offering of Common Stock
SAB Biotherapeutics announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the proposed offering are to be sold by SAB BIO. The company intends to use the net proceeds it receives from this offering, together with its existing cash, cash equivalents and marketable securities, primarily to fund the continued development of our clinical stage product candidate, SAB-142 through ongoing and planned clinical trials, as well as for related manufacturing, regulatory, and operational activities, and for working capital and general corporate purposes. Jefferies, UBS Investment Bank, Citigroup, and Barclays are acting as joint book-running managers for the offering. Chardan is acting as lead manager.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.